Literature DB >> 2808204

Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.

M D Kitzis1, J F Acar, L Gutmann.   

Abstract

Meropenem, like imipenem, showed a good affinity for high molecular weight PBPs of Escherichia coli and Pseudomonas aeruginosa and had a better affinity for PBP3 than imipenem. Meropenem, like imipenem, also remained almost fully active against permeability mutants of enterobacteria lacking in confirmed or putative porins. This good permeation of the carbapenems may relate to their zwitterionic character. In-vitro, mutants and clinical isolates of P. aeruginosa, for which the MIC of imipenem was greater than or equal to 4 mg/l, were always more sensitive to meropenem. Methicillin resistant staphylococci were sensitive neither to imipenem nor to meropenem.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808204     DOI: 10.1093/jac/24.suppl_a.125

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem.

Authors:  H Yano; A Kuga; R Okamoto; H Kitasato; T Kobayashi; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.

Authors:  Rajnikant Sharma; Saloni Patel; Cely Abboud; John Diep; Neang S Ly; Jason M Pogue; Keith S Kaye; Jian Li; Gauri G Rao
Journal:  Int J Antimicrob Agents       Date:  2016-12-23       Impact factor: 5.283

Review 4.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

6.  WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 7.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

8.  Pharmacodynamic effects of meropenem on gram-negative bacteria.

Authors:  H Hanberger; E Svensson; L E Nilsson; M Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

9.  Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.

Authors:  J C Fung-Tomc; E Huczko; J Banville; M Ménard; B Kolek; E Gradelski; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Authors:  J C Fung-Tomc; E Gradelski; B Kolek; B Minassian; M Pucci; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.